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Abstract
Background: Disclosure of amyloid positron emission tomography (PET) results to individuals without dementia
has become standard practice in secondary prevention trials and also increasingly occurs in clinical practice.
However, this is controversial given the current lack of understanding of the predictive value of a PET result at the
individual level and absence of disease-modifying treatments. In this study, we systematically reviewed the literature
on the disclosure of amyloid PET in cognitively normal (CN) individuals and patients with mild cognitive
impairment (MCI) in both research and clinical settings.
Methods: We performed a systematic literature search of four scientific databases. Two independent reviewers
screened the identified records and selected relevant articles. Included articles presented either empirical data or
theoretical data (i.e. arguments in favor or against amyloid status disclosure). Results from the theoretical data were
aggregated and presented per theme.
Results: Of the seventeen included studies, eleven reported empirical data and six provided theoretical arguments.
There was a large variation in the design of the empirical studies, which were almost exclusively in the context of
cognitively normal trial participants, comprising only two prospective cohort studies quantitatively assessing the
psychological impact of PET result disclosure which showed a low risk of psychological harm after disclosure. Four
studies showed that both professionals and cognitively normal individuals support amyloid PET result disclosure
and underlined the need for clear disclosure protocols. From the articles presenting theoretical data, we identified
51 ‘pro’ and ‘contra’ arguments. Theoretical arguments in favor or against disclosure were quite consistent across
population groups and settings. Arguments against disclosure focused on the principle of non-maleficence,
whereas its psychological impact and predictive value is unknown. Important arguments in favor of amyloid
disclosure are the patients right to know (patient autonomy) and that it enables early future decision making.
Discussion: Before amyloid PET result disclosure in individuals without dementia in a research or clinical setting is
ready for widespread application, more research is needed about its psychological impact, and its predictive value
at an individual level. Finally, communication materials and strategies to support disclosure of amyloid PET results
should be further developed and prospectively evaluated.
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Background
Amyloid-β aggregation in the brain is one of the neu-
ropathological hallmarks of Alzheimer’s disease (AD)
[1–3]. The introduction of 11-labeled Pittsburgh Com-
pound B made it possible to detect amyloid-β deposition
in vivo using positron emission tomography (PET) [4].
As part of the paradigm shift from clinical diagnoses to
biomarker-supported diagnoses, amyloid PET has been
incorporated as a biomarker in the diagnostic criteria for
dementia and mild cognitive impairment (MCI) due to
AD [5–9]. In addition, to stimulate studies assessing
disease-modifying therapies at an early stage of disease,
research criteria were introduced to define cognitively
normal individuals with elevated cerebral amyloid-β as
having preclinical AD [10, 11]. The advent of 18F-labeled
amyloid PET ligands allowed widespread use for re-
search purposes, while its subsequent regulatory agen-
cies approval opened the way for use in clinical practice
[12–15].
Given the lack of understanding of the predictive value
of amyloid PET at an individual level [16–22], interpreting
and communicating a PET result to amyloid-positive indi-
viduals who are not demented (yet) is challenging, and its
impact has hardly been investigated [23]. Nevertheless,
amyloid PET is already incorporated in anti-amyloid trials
(> 15) as a screening instrument to identify individuals
with Alzheimer’s pathology, either cognitively normal
(CN) or with MCI, and result disclosure is a necessity of
design [24, 25]. In addition, appropriate use criteria for
clinical PET use indicate that patients with MCI could be
considered for amyloid imaging to identify the underlying
etiology, while CN individuals are considered inappropriate
to scan given the limited prognostic value of PET [26, 27].
Taken together, amyloid PET result disclosure is in-
creasingly being used in both research and clinical prac-
tice for different purposes, while evidence on its impact
and safety is lagging behind. The aim of the current
study was to systematically review the literature on the
disclosure of amyloid PET in CN individuals and pa-
tients with MCI in both research and clinical settings.
Methods
Data search
This systematic review is based on the Preferred Reporting
Items for Systematic Reviews and Meta-Analysis (PRISMA)
statement [28]. We conducted a systemic literature search
in four electronic databases on 28 March 2017: Embase,
PubMed, the Cochrane library, and Web of Science. We
developed the search strategy in collaboration with an in-
formation specialist from the VU Medical Center medical
library. Search terms included controlled terms (MeSH in
PubMed and Emtree in Embase) as well as free text terms.
We used free text terms only in the Cochrane library.
Search terms used were variations on the keywords
‘Alzheimer or dementia’, in combination with search terms
comprising ‘disclosure’ and combined with search terms
comprising ‘biomarker’ or ‘amyloid’. The full search strat-
egies for all databases are presented in Additional file 1.
The references of the included articles were further
searched for relevant publications.
Inclusion and exclusion criteria
We included articles if they reported on disclosure of
amyloid PET results in patients with MCI and CN individ-
uals. Given the limited number of studies with empirical
data (e.g., randomized controlled trials, surveys, multiple
case studies) we also considered reviews, perspectives, and
point-of-views addressing theoretical arguments in favor
or against amyloid PET disclosure. Articles had to be pub-
lished in peer-reviewed journals, and all languages were
accepted.
Study selection
Our database search resulted in 2664 unique articles after
removing duplicates. Titles and abstracts of all the identi-
fied articles were screened by two independent reviewers
(AdW and MMvB). Screening for the title and abstract re-
sulted in 228 articles for full-text assessment for eligibility.
The same two reviewers assessed all full-text articles. In
case of discrepancy, consensus was reached after discus-
sion and consultation of a third reviewer (WMvdF). We
included 15 articles for data extraction and data synthesis
[5, 10, 29–41]. A flowchart that shows the results of the
initial study selection is presented in Fig. 1. We addition-
ally included two relevant articles that were published
after we conducted our search [42, 43], resulting in a total
of 17 articles.
Data extraction and synthesis
Empirical data were extracted by two reviewers (AdW
and MMvB), discussed, and checked by a third reviewer
(WMvdF). We extracted data regarding main outcome
measures and additional information on study design,
population characteristics, methods, other relevant out-
come measures, and the conclusions of the authors.
Arguments in favor or against disclosure in theoretical
papers were identified and extracted by two reviewers
(AdW and MMvB). In case of discrepancies between the
reviewers, consensus was reached after discussion and
consultation of a third reviewer (WMvdF). Due to a
large variation in the content of the arguments, we com-
posed a meta-summary. Finally, we grouped empirical
data and arguments based on both the context (research
versus clinic) and the population (CN versus MCI) for
which the authors used them.
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Results
Of the fifteen included studies, nine reported empirical
data on an aspect of amyloid PET result disclosure, while
six provided theoretical arguments in favor or against
disclosure.
Empirical data in a research context
There was a large variation in the research questions
and designs of the empirical studies, with two prospect-
ive cohort studies, three randomized controlled trials,
three surveys, and a modified Delphi study. Table 1
shows an overview of the studies reporting empirical
data.
Researchers’ attitudes towards disclosure
Prior to the Food and Drug Administration (FDA) ap-
proval of 18F-florbetapir, Alzheimer’s Disease Neuroim-
aging Initiative (ADNI) investigators and research staff
(n = 159) were interviewed about whether ADNI should
change its policy of not returning amyloid imaging
results [37]. Of interviewees with direct participant con-
tact (n = 139), 45% reported that CN participants had
never requested their PET results, and 40% reported this
for participants with MCI. From the ADNI investigators,
94% reported that they “never” disclosed PET results to
CN participants, while 90% did not return results to par-
ticipants with MCI. A majority of respondents indicated
that, upon FDA approval for 18F-florbetapir, they would
support disclosing amyloid imaging results to MCI pa-
tients (73%) and participants with normal cognition
(58%). Important reasons favoring disclosure (based on
free-text answers) were based on the principles of ‘re-
spect for autonomy’ and the ‘right to know’, and that it
enables future planning and lifestyle changes, while con-
cerns were expressed about potential psychological
harms and impact on insurance. Respondents who en-
dorsed disclosure stressed the need for developing stan-
dardized disclosure procedures, with the disclosure
procedure needing to be rigorously studied with longitu-
dinal outcomes to assess well-being.
Fig. 1 PRISMA flow diagram illustrating the process of study selection. AD Alzheimer’s disease
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Cognitively normal study participants’ attitudes towards
disclosure
Three studies assessed study participants’ interest in
knowing their amyloid PET status, albeit using different
research questions and study designs. One study sur-
veyed the interest of CN participants (n = 164) in an Alz-
heimer’s prevention registry in knowing their amyloid
status and their motivations [36], and 81% of partici-
pants expressed a wish to know their amyloid status,
motivated by a desire to participate in AD research
(73%) and to prepare their family for their illness (60%).
Almost 12% indicated they would use the information to
make plans for ending their life when memory loss be-
comes imminent. The main reason for not being inter-
ested in their amyloid status was because of the
expectation of feeling depressed when amyloid was ele-
vated (40%). The second study randomly assigned CN
participants (n = 219) in a longitudinal aging study to an
education intervention (n = 119) or placebo (n = 100) to
measure pre- and postintervention interest in biomarker
disclosure [32]. One of the items was interest in amyloid
imaging results. The authors observed a high preinter-
vention interest (mean 4.0 ± 1.1 on a five-point Likert
scale, with 5 being extremely interested) in receiving
amyloid PET results. After controlling for preinterven-
tion level of interest, an ordinal logistic regression
showed that assignment (education versus placebo) sig-
nificantly decreased interest (odds ratio (OR) 2.8, 95%
confidence interval (CI) 1.6–5.1; p < 0.001), with the ex-
emption of three subgroups: participants who 1) esti-
mated their subjective AD risk greater than 50% (the
mean), 2) reported having at least one parent with AD,
and 3) attended few participant meetings. The third
study assessed the likelihood of trial enrollment in older
community volunteers with self-reported normal cogni-
tion (n = 132) after randomly assigning them to a hypo-
thetical informed consent form where amyloid PET
result disclosure was either present (transparent, n = 66)
or absent (blinded, n = 66) [33]. There was no significant
difference in the likeliness to enroll in clinical trials be-
tween the two groups (70% versus 61%).
Impact of disclosure
Two studies assessed the impact of amyloid PET disclos-
ure on depression, anxiety, and stress, while two studies
performed semi-structured interviews to assess experi-
ences after PET disclosure. The first study compared
measures of depression, anxiety, and test-related distress
at different time points between amyloid-positive (n =
27) and amyloid-negative (n = 70) trial participants [31].
Depressive symptoms were stable across visits and were
not different between groups. For anxiety symptoms,
there was a small increase immediately post-disclosure
in the amyloid-positive group, which was not sustained.
However, post-hoc analyses revealed no group differ-
ences at any time point. Amyloid-positive individuals
had slightly higher levels of distress after PET result dis-
closure, and these were related to higher baseline levels
of depression and anxiety. The second study assessed
depression, anxiety, stress, impact of events, and subject-
ive memory complaints in a small number of CN trial
participants (n = 11) who explicitly requested their amyl-
oid status and which they received after reading a psy-
choeducational brochure [35]. Despite an insufficient
number to make formal comparisons, the impact of
disclosure did not seem to be different between
amyloid-positive (n = 3) and amyloid-negative (n = 8) par-
ticipants. Participants considered the psychoeducational
brochure to be very useful, and disclosure of amyloid posi-
tivity seemed to motivate lifestyle changes. The third study
performed two semi-structured post-disclosure interviews
with MCI patients (n = 38) as a substudy of a clinical trial
in which participants could opt to know their PET result
[42]. The results were assessed using qualitative content
analysis. Most patients could recall the core message of
their result disclosure in their own words. Two out of
eight amyloid-positive patients experienced emotional dif-
ficulties (feeling worried, sadness) post-disclosure, whereas
three of thirty amyloid-negative patients doubted whether
they had received the correct result. Experienced ad-
vantages included the possibility of making practical ar-
rangements. The fourth study performed semi-structured
post-disclosure telephone interviews with 26 patient-care-
giver dyads with whom a neurologist discussed the option
of amyloid PET [43]. Clinical reasons for scanning varied
but were generally considered consistent with the appro-
priate use criteria for amyloid imaging [26]. Most patients
who chose to undergo amyloid imaging would opt for the
scan again. Regardless of the PET result, patient and care-
givers commonly expressed relief on learning the results.
Some patients had expectations of the PET scan that are
beyond its capabilities.
Development of an approach for amyloid disclosure
Two studies reported on the development of amyloid PET
disclosure materials in the context of clinical trials. The
first study developed a process to maximize safety and ef-
fectiveness of disclosing amyloid imaging results to CN
older adults participating in AD secondary preventions
studies. They used a modified Delphi Method, consulting
experts in the field of genetic testing and amyloid PET, to
develop a consensus on best practices. Consensus was
reached on the text for a brochure and a disclosure
process. Recommendations included pretest counseling,
screening for anxiety and depression, separate days for
consent procedure, imaging, and disclosure, and follow-up
to monitor the impact of disclosure, anxiety, and depres-
sion. The developed process and documents are currently
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used in the Anti-Amyloid Treatment in Asymptomatic
Alzheimer’s Disease (A4) study [29]. The second study de-
veloped an approach for disclosure of amyloid imaging re-
search results in patients with MCI [30]. They used
simulated sessions during which MCI patients and their
care dyads received fictitious but realistic information re-
garding their amyloid status, satisfaction surveys, compre-
hension assessments, and focus group data to evaluate the
disclosure material. Recommendations included pretest
counseling, the use of participants’ own brain images dur-
ing disclosure, take-home materials, and follow-up to ad-
dress emerging questions. The materials are currently
used for trials at the University of Pittsburgh Alzheimer
Disease Research Center.
Empirical data in a clinical context
Dementia specialists’ attitudes towards disclosure
A cross-sectional survey among neurologists who spe-
cialized in dementia (n = 135) at US medical schools de-
scribed their attitudes towards their intention to use
amyloid imaging in clinical practice [34]. Of these, 84%
affirmed their intention to use amyloid PET for evidence
for (77%) or against (73%) a diagnosis of AD in
cognitively impaired patients, while 24% intended to use
amyloid PET for screening asymptomatic individuals.
Most respondents (92%) felt that patients should be
counseled in advance. A minority (16%) did not intend
to use amyloid imaging, and they expressed concerns
about costs, lack of improvement on existing diagnostic
tools, and likelihood of misinterpretation of results by
both patients and physicians.
Studies presenting theoretical arguments From six ar-
ticles, we identified a total of 51 arguments in favor (n =
22) or against (n = 29) amyloid PET result disclosure. We
assessed which population (CN versus MCI) and context
(research versus clinic) the authors used the arguments
for. Subsequently, we grouped arguments into the follow-
ing themes: ethical, social and legal, psychological and be-
havioral, and PET imaging characteristics (Table 2). Four
studies focused their arguments on CN individuals, where
their arguments where interchangeable (except for one)
for a research or clinical context [10, 38, 40, 41]. Two
studies provided arguments on individuals with MCI; one
in a research and one in a clinical setting [5, 39]. There
was considerable overlap between arguments regarding
Table 2 Overview of theoretical arguments in favor or against amyloid positron emission tomography (PET) result disclosure
Cognitively normal Mild cognitive impairment
Category Arguments Research Clinic Research Clinic
Pro
Ethical Patient autonomy X10,41 X10,41 X39 X5
Evidence of non-maleficence X10,40,41 X10,40,41
Social and legal Cost and suffering reduction X38 X38
Favors Alzheimer’s disease prevention X10 X10
Psychological and behavioral Enables early decision making X10,38,41 X10,38,41 X39 X5
Clarifying effect of correct diagnosis X38 X38 X39 X5
Relief related to negative amyloid PET X38,41 X38,41
Satisfies need for risk information X41 X41
PET imaging characteristics Amyloid PET imaging is validated X39
Clinical significance of amyloid PET X5
Contra
Ethical Non-maleficence X10,38,41 X10,38,41 X39 X5
Lack of effective intervention X10,38 X10,38 X39
Therapeutic misconception X2 X2
Social and legal Unwanted personal implications X38,41 X10,38,41 X5
Social stigmatization X38,41 X38,41
Psychological and behavioral Risk of psychological distress X10,38,41 X10,38,41 X5
Risk of false reassurance after negative PET X10,41 X10,41 X39
Misinterpretation of positive amyloid PET X41 X41
PET imaging characteristics Challenges related to inconclusive scans X10,38 X10,38 X5
Limited predictive value at level of individual X10,41 X10,41
Variation on interpretation of PET results X10 X10
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CN individuals or individuals with MCI, regardless of the
context. For that reason, we decided to present arguments
in favor or against disclosure grouped together.
Arguments in favor of PET result disclosure
Frequently used arguments in favor of amyloid PET dis-
closure were based on the ethical principles of patient
autonomy and non-maleficence (not to harm). Respect
for patient autonomy is a foundation of medical ethics
and is based on the notion that individuals should be
able to make personal decisions based on their evalu-
ation of the personal risks and benefits [10]. The argu-
ment of non-maleficence is mostly based on the parallel
between amyloid PET disclosure and disclosure of apoli-
poprotein E (APOE) genotype, and the observation that
in the latter case disclosure did not increase depression,
anxiety, or stress [10, 40, 41]. In addition, amyloid PET
result disclosure could potentially enable early decision
making in terms of lifestyle changes (e.g., diet, exercise,
cognitive training), trial participation, and planning for
the future, while individuals still have full decision com-
petence [5, 10, 38, 39, 41]. Also, a correct diagnosis
using amyloid PET may be clarifying and appreciated by
patients and their relatives, and add to a better under-
standing of their complaints and prognosis [5, 38, 39].
Notably, the argument that amyloid PET imaging is vali-
dated for use and that its clinical significance has been
sufficiently established were only used in the context of
result disclosure to individuals with MCI [5, 39].
Arguments against PET result disclosure
The most frequently used arguments against amyloid
PET result disclosure were based on the ethical principle
of avoiding potential harms, such as psychological
distress (e.g., anxiety, depression, stress), or negative
social-legal consequences (e.g., increased insurance pre-
miums, the right to drive, maintain employability, or re-
tain legal competence), especially in the absence of an
effective disease-modifying treatment [5, 38, 41]. An-
other potential risk of disclosure is social stigmatization,
whereby individuals can encounter discrimination in
their social life or at the workplace [38, 41]. Finally, the
predictive value of amyloid PET at an individual level is
limited and warrants further research [10, 41].
Discussion
Our systematic review of the literature on disclosure of
amyloid PET results to individuals without dementia
(cognitively normal and mild cognitive impairment) in
both research and clinical contexts shows that the
current body of empirical data is very weak. Theoretical
arguments in favor or against disclosure were quite con-
sistent across population groups and settings. Sparsely
available data suggest that dementia specialists support
disclosure in MCI patients clinically, while most researchers
support disclosing amyloid PET results to individuals with-
out dementia in research and they stress the importance of
pretest counseling in this context. Cognitively normal indi-
viduals in a research setting are interested in learning about
their amyloid status, and preliminary results show their risk
of psychological harm seems low. There is a complete lack
of studies in a clinical setting, however.
Three studies assessed the interests of cognitively nor-
mal individuals in learning about their amyloid PET re-
sults in a trial setting using very different designs [32,
33, 36]. Interest in disclosure of individual PET results
was high in all studies, but somewhat tempered after
learning the limitations of disclosure. One study re-
ported that > 10% of patients indicated they would use
the information of a positive PET to make plans for end-
ing their life when memory loss becomes imminent [36].
A previous study on public perceptions of presymptom-
atic testing of AD reported a similar estimate, further
emphasizing the need for psychological screening to
identify individuals at a high risk of adverse psycho-
logical outcomes [44]. Within this context, requiring
study partners for enrollment could be essential to en-
sure patient safety [45]. ADNI researchers were also in
favor of disclosing amyloid PET results in a research set-
ting, but stressed the need for pretest counseling and
guidance on disclosure procedures [34, 37]. Of note, des-
pite the fact that ADNI researchers were in favor of dis-
closing amyloid PET results, their preference has not
been put into practice. In accordance, dementia special-
ists at US medical schools affirmed their intention to use
amyloid PET in clinical practice for cognitively impaired
individuals, while a small minority intent to use amyloid
PET to screen asymptomatic individuals. These results
illustrate that stakeholders are in agreement about amyl-
oid results disclosure to CN and MCI individuals in a re-
search setting while, in a clinical setting, this agreement
is restricted to MCI individuals. Nevertheless, a recent
study has demonstrated that amyloid PET has clinical
impact in some individuals with subjective cognitive de-
cline, while its usefulness in this population is currently
also under investigation in the Amyloid Imaging to Pre-
vent Alzheimer’s Disease (AMYPAD) study. Addition-
ally, the importance of providing solid information on
amyloid imaging and management of expectations with
regard to the results is stressed [46–48].
Only two studies quantitatively assessed the effects of
actual amyloid PET disclosure, both in cognitively normal
individuals in a trial setting [31, 35]. Based on their results,
it seems that disclosure of both positive and negative PET
results has a low risk of psychological harm. Two studies
that qualitatively assessed semi-structured interviews per-
formed post-disclosure with either cognitively impaired
study participants or their caregivers also reported few
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negative psychological outcomes, while some participants
expressed a feeling of relief, even after a positive PET re-
sult [42, 43]. In addition, in an unselected memory clinic
cohort, including patients with subjective cognitive decline
(SCD) and MCI, subgroup analyses revealed unchanged
measures of anxiety, and a decrease in uncertainty follow-
ing amyloid PET [49]. However, it must be noted that the
sample sizes of the studies were small, and most studies
consisted of very select research populations. For example,
participants were highly educated, and exclusion criteria in-
cluded a history of neurological or psychiatric disorders,
any significant systemic illness, or unstable medical condi-
tion. Given this common selection of very healthy and
highly motivated research participants, the risk of adverse
psychological events is probably reduced compared with an
average clinical population. Thus far, quantitative data in a
clinical setting are lacking completeness and the psycho-
logical effects of amyloid PET result disclosure could be
very different in a patient population that attends a memory
clinic. These patients will on average be less educated and
have more physical and psychiatric comorbidity. Further
studies are needed to assess the psychological risks in (clin-
ical) populations.
Two studies developed a process to maximize the safety
and effectiveness of amyloid PET result disclosure, and to
guide the design and conduct of clinical trials that would
require its disclosure (e.g., the A4 study) [29, 30]. The rec-
ommendations of both disclosure procedures, developed
for CN individuals and individuals with MCI, were very
similar. Recommendations included pretest counseling,
pre- and post-disclosure monitoring of its psychological
impact, and using separate days for counseling, imaging,
and disclosure. A small but noticeable difference between
the studies was the recommendation to use an individual’s
own brain image for disclosure in the A4 study protocol.
Recent findings from an A4 substudy on comprehension
of positive PET results underline this recommendation;
participants expressed a ‘desire for more specific, dimen-
sional and quantitative information’, rather than a qualita-
tive and dichotomous result [50].
Theoretical arguments in favor or against disclosure
were quite consistent across population groups and set-
tings. These similarities might demonstrate that it is not
merely the arguments themselves that shape opinions on
disclosure, but rather their varying ‘weight’ and ‘signifi-
cance’ when used in different contexts. For individuals
with MCI, there generally seems to be support for amyl-
oid result disclosure, regardless of the setting, given that
it is already part of research and clinical practice. How-
ever, the best approach to do so has yet to be deter-
mined. For CN individuals, on the contrary, there is a
certain dichotomy [10]. Despite the lack of data on
amyloid disclosure safety and effectiveness, and despite
counter arguments, disclosure of amyloid status is
common practice in the context of secondary AD pre-
vention trials, while these same arguments are used to
argue that disclosure is premature in a clinical setting.
Contrary to the paucity of data on amyloid PET disclos-
ure, much more is known about the psychological and be-
havioral impact of disclosure of genetic biomarkers, such as
the APOE e4 genotype [23]. In cognitively healthy individ-
uals, disclosure of APOE e4 positivity is not associated with
higher levels of anxiety and depression but it increases
test-related distress. In addition, long-term care insurance
uptake and health-related behavior changes increased, while
it might affect subjective and objective memory function-
ing. However, it must be noted that research cohorts con-
sisted almost exclusively of research participants without
psychological complaints at baseline who had first-degree
relatives with AD, limiting generalizability to other settings
and groups. When comparing APOE e4 status disclosure
with amyloid PET result disclosure, there are some major
differences. First, carrying an APOE e4 allele is a risk factor
for developing AD but, contrary to amyloid PET, does not
reflect the presence of an ongoing pathophysiological
process (i.e., the accumulation of brain amyloid beta). Sec-
ond, APOE e4 studies almost exclusively assessed cogni-
tively healthy research participants with a family history of
AD, and these individuals may already suspect they are at
increased risk for AD based on their positive family history.
Limitations of this systematic review are related to the
limited body of literature on the topic of the effects of
amyloid PET results disclosure. Studies were mainly fo-
cused on research settings and had widely different re-
search questions and study designs. Only a few studies
had quantitative outcome measures, and these were
mainly focused on anxiety, depression, and stress. Given
the potential impact of amyloid PET disclosure, it would
also be interesting to assess its impact on employment,
personal healthcare plans including lifestyle modifica-
tion, and long-term planning. Available studies were
mainly focused on amyloid disclosure in cognitively nor-
mal participants in the context of clinical trials, hamper-
ing translation of the results to clinical practice.
Conclusions
This systematic review highlights the lack of data on amyl-
oid PET result disclosure to individuals without dementia,
especially in a clinical setting, and stresses the strong need
for more studies in this context. This is critical for better
understanding disclosure impact at a time when the use of
amyloid PET is increasing in secondary AD prevention tri-
als, and patients with SCD represent up to 25% of the clin-
ical population [49]. The sparse data available suggest that
disclosure of amyloid PET results has a low risk of
psychological harm in the context of clinical trials,
whereas both participants and professionals seem to sup-
port disclosure. Before amyloid PET result disclosure in
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individuals without dementia is ready for widespread ap-
plication, more research is needed about its psychological
impact, and its predictive value at an individual level. Fi-
nally, communication materials and strategies to support
disclosure of amyloid PET results should be further devel-
oped and prospectively evaluated.
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